Bristol-Myers Squibb’s Yervoy (ipilimumab) awarded Prix Galien USA Discovery of the Decade
Bristol-Myers Squibb announced that it received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the Company’s recombinant, human monoclonal antibody. Yervoy is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma. October 28, 2016